LabGenomics Co., Ltd.

KOSDAQ:A084650 Stock Report

Market Cap: ₩275.4b

LabGenomics Past Earnings Performance

Past criteria checks 0/6

LabGenomics's earnings have been declining at an average annual rate of -25.1%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been declining at an average rate of 0.9% per year.

Key information

-25.1%

Earnings growth rate

-25.1%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate-0.9%
Return on equity-10.4%
Net Margin-26.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There's No Escaping LabGenomics Co., Ltd.'s (KOSDAQ:084650) Muted Revenues Despite A 46% Share Price Rise

Jan 06
There's No Escaping LabGenomics Co., Ltd.'s (KOSDAQ:084650) Muted Revenues Despite A 46% Share Price Rise

Not Many Are Piling Into LabGenomics Co., Ltd. (KOSDAQ:084650) Stock Yet As It Plummets 26%

Nov 17
Not Many Are Piling Into LabGenomics Co., Ltd. (KOSDAQ:084650) Stock Yet As It Plummets 26%

Is LabGenomics (KOSDAQ:084650) Weighed On By Its Debt Load?

Nov 08
Is LabGenomics (KOSDAQ:084650) Weighed On By Its Debt Load?

Slammed 29% LabGenomics Co., Ltd. (KOSDAQ:084650) Screens Well Here But There Might Be A Catch

Sep 21
Slammed 29% LabGenomics Co., Ltd. (KOSDAQ:084650) Screens Well Here But There Might Be A Catch

Market Might Still Lack Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650) Even After 35% Share Price Boost

Aug 06
Market Might Still Lack Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650) Even After 35% Share Price Boost

Is LabGenomics (KOSDAQ:084650) Using Too Much Debt?

Jul 27
Is LabGenomics (KOSDAQ:084650) Using Too Much Debt?

Market Still Lacking Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650)

Apr 09
Market Still Lacking Some Conviction On LabGenomics Co., Ltd. (KOSDAQ:084650)

If You Like EPS Growth Then Check Out LabGenomics (KOSDAQ:084650) Before It's Too Late

Mar 31
If You Like EPS Growth Then Check Out LabGenomics (KOSDAQ:084650) Before It's Too Late

Revenue & Expenses Breakdown

How LabGenomics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A084650 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2485,817-22,33641,5563,257
30 Jun 2485,341-21,17539,5813,030
31 Mar 2478,360-18,03836,0562,747
31 Dec 2373,127-4,67431,5902,812
30 Sep 2369,8484,13525,5532,390
30 Jun 2373,18813,55823,3892,290
31 Mar 2379,80414,48324,7151,807
31 Dec 22144,77348,39726,1701,865
30 Sep 22187,00974,15123,5001,398
30 Jun 22215,95290,80023,0801,289
31 Mar 22248,011108,70221,2841,490
31 Dec 21202,40783,85518,484557
30 Sep 21173,03964,68218,264256
30 Jun 21146,33649,14816,7510
31 Mar 21141,63253,80216,3340
31 Dec 20119,47842,76615,2130
30 Sep 2097,27938,38213,9930
30 Jun 2078,95629,47913,0790
31 Mar 2038,2373,17510,7200
31 Dec 1933,17596210,6990

Quality Earnings: A084650 is currently unprofitable.

Growing Profit Margin: A084650 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A084650 is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.

Accelerating Growth: Unable to compare A084650's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A084650 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).

Return on Equity

High ROE: A084650 has a negative Return on Equity (-10.38%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 03:54
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LabGenomics Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimHanwha Investment & Securities Co., Ltd.
Wan KuiM Securities
Seung Kyu JungKiwoom Securities Co., Ltd.